Posted by Michael Wonder on 23 Apr 2024
Health Canada approves new indication for Merck’s Prevymis (letermovir) for prevention of cytomegalovirus disease in high risk adult kidney transplant recipients
19 April 2024 - Merck announced that Health Canada has approved a new indication for Prevymis (letermovir) for the prophylaxis of cytomegalovirus (CMV) disease in adult kidney transplant recipients at high risk (donor CMV seropositive/recipient CMV seronegative [D+/R-]).
Health Canada’s approval of Prevymis for CMV disease prophylaxis in adult kidney transplant recipients was supported by a Phase 3, randomised, multi-centre, double-blind, active comparator-controlled non-inferiority trial (P002) in 589 adult kidney transplant recipients at high risk (CMV D+/R-).
